SVB Leerink

DGAP-News: Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Thursday, October 14, 2021 - 12:08pm

NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.

Key Points: 
  • NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.
  • "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies.
  • He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development.

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Thursday, October 14, 2021 - 11:30am

In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic.

Key Points: 
  • In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic.
  • "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies.
  • He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development.

Bicycle Therapeutics Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares

Wednesday, October 13, 2021 - 5:38am

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced the pricing of an underwritten public offering of 3,240,741 American Depositary Shares (ADSs), each representing one ordinary share, at a price to the public of $54.00 per ADS, for gross proceeds of $175.0 million.

Key Points: 
  • Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced the pricing of an underwritten public offering of 3,240,741 American Depositary Shares (ADSs), each representing one ordinary share, at a price to the public of $54.00 per ADS, for gross proceeds of $175.0 million.
  • In addition, Bicycle has granted the underwriters in the offering a 30-day option to purchase up to 486,111 additional ADSs at the public offering price.
  • Goldman Sachs & Co. LLC, Morgan Stanley and SVB Leerink are acting as joint book-running managers for the offering.
  • There can be no assurance that Bicycle will be able to complete the offering on the anticipated terms, or at all.

Bicycle Therapeutics Announces Proposed $125,000,000 Public Offering of American Depositary Shares

Tuesday, October 12, 2021 - 11:57am

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that it has commenced an underwritten public offering of $125,000,000 of American Depositary Shares (ADSs), each representing one ordinary share.

Key Points: 
  • Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that it has commenced an underwritten public offering of $125,000,000 of American Depositary Shares (ADSs), each representing one ordinary share.
  • All of the ADSs in the proposed offering will be sold by Bicycle.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.
  • Forward-looking statements contained in this press release include statements relating to Bicycles expectations regarding the size, completion and terms of the proposed public offering and Bicycles planned use of the proceeds from the proposed public offering.

Xenon Pharmaceuticals Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Friday, October 8, 2021 - 7:15pm

BURNABY, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares, which includes 1,525,423 shares sold upon the full exercise of the underwriters option to purchase additional shares, and pre-funded warrants to purchase 1,694,915 common shares.

Key Points: 
  • BURNABY, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares, which includes 1,525,423 shares sold upon the full exercise of the underwriters option to purchase additional shares, and pre-funded warrants to purchase 1,694,915 common shares.
  • The aggregate gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were approximately $345.0 million.
  • Jefferies, SVB Leerink, Stifel and RBC Capital Markets acted as joint book-running managers for the offering.
  • The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.

Xenon Pharmaceuticals Announces Pricing of $300.0 Million Public Offering

Wednesday, October 6, 2021 - 2:54am

The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $300.0 million.

Key Points: 
  • The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $300.0 million.
  • In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,525,423 common shares at the public offering price, less the underwriting discounts and commissions.
  • The offering is expected to close on or about October 8, 2021, subject to customary closing conditions.
  • These forward-looking statements are not based on historical fact and include statements regarding the anticipated closing of the public offering.

Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma

Tuesday, October 5, 2021 - 9:05pm

Xeris Pharmaceuticals, Inc. (Xeris), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (Strongbridge).

Key Points: 
  • Xeris Pharmaceuticals, Inc. (Xeris), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (Strongbridge).
  • Under the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdings, Inc. (Xeris Biopharma Holdings).
  • The minimum payment on the CVR per Strongbridge ordinary share is zero and the maximum payment is $1.00 in cash or Xeris Biopharma Holdings common stock, at Xeris Biopharma Holdings election.
  • Following the close of the transaction, former Xeris shareholders own approximately 60% of Xeris Biopharma Holdings, while former Strongbridge shareholders own approximately 40%.

Xenon Pharmaceuticals Announces Proposed Public Offering

Monday, October 4, 2021 - 9:08pm

BURNABY, British Columbia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $250 million of its common shares pursuant to its existing shelf registration statement.

Key Points: 
  • BURNABY, British Columbia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $250 million of its common shares pursuant to its existing shelf registration statement.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
  • Jefferies, SVB Leerink, Stifel and RBC Capital Markets are acting as joint book-running managers for the offering.
  • These forward-looking statements are not based on historical fact and include statements regarding the anticipated public offering.

Roivant Sciences Announces Close of Business Combination with Montes Archimedes Acquisition Corp. and Concurrent PIPE Financing

Friday, October 1, 2021 - 1:00pm

At the close of this transaction on September 30, 2021, Roivants consolidated cash position is approximately $2.5 billion.

Key Points: 
  • At the close of this transaction on September 30, 2021, Roivants consolidated cash position is approximately $2.5 billion.
  • I would like to thank our new investors for their support as we continue to advance transformational medicines and novel modalities.
  • In addition, the company announced that Richard Pulik has joined Roivant as Chief Financial Officer.
  • SVB Leerink LLC served as a capital markets advisor to Roivant and as a lead placement agent for the PIPE.

Ensemble Health Partners Files Registration Statement for Proposed Initial Public Offering

Wednesday, September 29, 2021 - 9:53pm

CINCINNATI, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Ensemble Health Partners, Inc. (Ensemble), an industry leader in healthcare revenue cycle management, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial offering of its Class A common stock.

Key Points: 
  • CINCINNATI, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Ensemble Health Partners, Inc. (Ensemble), an industry leader in healthcare revenue cycle management, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial offering of its Class A common stock.
  • The number of shares to be offered and the price range for the proposed offering have not yet been determined.
  • Credit Suisse, Evercore ISI, Wells Fargo Securities, SVB Leerink, Baird, and William Blair are acting as joint bookrunners for the proposed offering.
  • Ensemble Health Partners is a leading provider of technology-enabled revenue cycle management (RCM) solutions for health systems, including hospitals and affiliated physician groups.